日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Immunogenicity and safety of biological E's 14-valent pneumococcal conjugate vaccine (PNEUBEVAX 14®) administered in a 2p + 1 schedule to healthy infants: a multicenter, randomized, active controlled, single-blind, phase III trial

一项多中心、随机、活性对照、单盲、III期临床试验，旨在评估生物制品公司E研发的14价肺炎球菌结合疫苗（PNEUBEVAX 14®）在健康婴儿中采用2p+1接种程序时的免疫原性和安全性。

期刊:Lancet Regional Health - Southeast Asia
影响因子:6.2
doi:10.1016/j.lansea.2026.100746
Thuluva, Subhash; Matur, Ramesh V; Gunneri, Subbareddy; Ningaiah, Siddalingaiah; Yerroju, Vijay; Mogulla, Rammohan Reddy; Dhar, Chirag; Thammireddy, Kamal; Paliwal, Piyush; Kawade, Anand; Nanjappa, Pradeep; Pramod, Jog; Narang, Manish; Chakravarthy, Bheemisetty S; Virupakashappa, Prashanth M
肺炎
免疫/内分泌
发表日期：2026
文献求助 收藏

Investigating the Role of Diet-Manipulated Gut Bacteria in Pathogenesis of Type 2 Diabetes Mellitus-An In Vitro Approach

探讨饮食调控肠道菌群在2型糖尿病发病机制中的作用——一种体外方法

期刊:Nutrients
影响因子:5
doi:10.3390/nu18020279
Guraka, Asha; Lush, Marie; Zouganelis, Georgios; Waldron, Joe; Mekapothula, Subbareddy; Masania, Jinit; Cave, Gareth Wynn Vaughan; Conway, Myra Elizabeth; Tripathi, Gyanendra; Kermanizadeh, Ali
信号转导
代谢
微生物学
肠道菌群
糖尿病
发表日期：2026
文献求助 收藏

XRD and Molecular Dynamics Insights into Lattice Behavior of Oxide Nanocatalysts: The Case of CeO(2)

利用X射线衍射和分子动力学方法深入了解氧化物纳米催化剂的晶格行为：以CeO(2)为例

期刊:Nanomaterials
影响因子:4.3
doi:10.3390/nano16050333
Subbareddy, Sirisha; Malagutti, Marcelo Augusto; Nautiyal, Himanshu; Ataollahi, Narges; Scardi, Paolo
发表日期：2026
文献求助 收藏

Amino Acid-Coated Nanoparticles for Preservation of Cut Roses: Formulation and Performance

用于鲜切玫瑰保鲜的氨基酸包覆纳米颗粒：配方及性能

期刊:ACS Omega
影响因子:4.3
doi:10.1021/acsomega.6c00583
Kotoulas, Konstantinos T; Nair, Midhun D; Hinton, Thomas; Samad, Samia; Mekapothula, Subbareddy; Jiang, Yunhong; Burrows, Andrew D; Cave, Gareth W V; Xie, Ming
发表日期：2026
文献求助 收藏

Immunogenicity and Safety of Biological E's Monovalent rDNA Hepatitis B Vaccine (BEVAC(®)) in Neonates and Infants: A Multicentre, Randomized, Phase IV Non-Inferiority Trial

Biological E公司单价重组DNA乙型肝炎疫苗（BEVAC®）在新生儿和婴儿中的免疫原性和安全性：一项多中心、随机、IV期非劣效性试验

期刊:Viruses-Basel
影响因子:3.5
doi:10.3390/v18040472
Thuluva, Subhash; Gunneri, Subbareddy; Ningaiah, Siddalingaiah; Yerroju, Vijay; Mogulla, Rammohan Reddy; Dhar, Chirag; Thammireddy, Kamal; Esanakarra, Raju; Nanjappa, Pradeep; Mahantshetti, Niranjana S
免疫/内分泌
肝炎
发表日期：2026
文献求助 收藏

Corrigendum to 'Immunogenicity and safety of Biological E's CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or COVAXIN: A Prospective double-blind randomised phase III clinical study' [IJID Regions, volume 17 (2025) 100786]

对“Biological E 的 CORBEVAX™ 疫苗作为异源加强剂量在先前接种过两剂 COVISHIELD™ 或 COVAXIN 的成年志愿者中的免疫原性和安全性：一项前瞻性双盲随机 III 期临床研究”的更正 [IJID Regions，第 17 卷（2025 年）100786]

期刊:IJID Regions
影响因子:1.7
doi:10.1016/j.ijregi.2025.100831
Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy; Yerroju, Vijay; Mogulla, Rammohan Reddy; Thammireddy, Kamal; Ningaiah, Siddalingaiah; Dhar, Chirag; Binayke, Akshay; Zaheer, Aymaan; Awasthi, Amit; Narang, Shiva; Reddy, Naveen Chander; Pandey, Anil Kumar; Anjaneylu, Chitta Sitaram
免疫/内分泌
发表日期：2026
文献求助 收藏

Phosphatase PTPN22 functions as an adaptor in the mTORC2 complex

磷酸酶PTPN22在mTORC2复合物中发挥接头蛋白的作用。

期刊:EMBO Reports
影响因子:6.5
doi:10.1038/s44319-025-00576-5.
Keshav Gupta ,Nagalakshmi Kommineni ,Tanuja Bogadi ,Neeraja P Alamuru-Yellapragada ,Subbareddy Maddika
信号转导
mTOR
MTOR
Ptpn22
Ptpn2
发表日期：2025
文献求助 收藏

Safety and immunogenicity of booster doses of an XBB.1.5 RBD subunit COVID-19 vaccine among individuals aged 5-80 years in India: a phase 3, single-blind, randomised controlled trial

在印度5-80岁人群中，XBB.1.5 RBD亚单位COVID-19疫苗加强剂量的安全性和免疫原性：一项3期单盲随机对照试验

期刊:Lancet Regional Health - Southeast Asia
影响因子:6.2
doi:10.1016/j.lansea.2025.100642
Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy; Mogulla, Rammohan Reddy; Yerroju, Vijay; Dhar, Chirag; Ningaiah, Siddalingaiah; Panchakshari, Mallikarjuna; Gillurkar, Chandrashekhar S; Narang, Manish; Kisan, Shivnitwar Sachin; Rao, A Venkateshwar
免疫/内分泌
发表日期：2025
文献求助 收藏

Beyond immunogenicity in XBB.1.5 subunit COVID-19 boosters focusing on durability, dosing, and target populations: authors reply

除了XBB.1.5亚单位COVID-19加强针的免疫原性之外，还应关注其持久性、剂量和目标人群：作者回复

期刊:Lancet Regional Health - Southeast Asia
影响因子:6.2
doi:10.1016/j.lansea.2025.100678
Thuluva, Subhash; Paradkar, Vikram; Gunneri, SubbaReddy; Mogulla, Rammohan Reddy; Yerroju, Vijay; Ningaiah, Siddalingaiah; Panchakshari, Mallikarjuna; Dhar, Chirag
免疫/内分泌
发表日期：2025
文献求助 收藏

Immunogenicity and safety of a multi-human dose formulation of Biological E's 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14(®)) administered to 6-8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study

一项针对6-8周龄健康婴儿的3期单盲、随机、活性对照研究，评估了Biological E公司14价肺炎球菌多糖结合疫苗（PNEUBEVAX 14®）多剂量制剂的免疫原性和安全性。

期刊:Frontiers in Immunology
影响因子:5.9
doi:10.3389/fimmu.2025.1550227
Thuluva, Subhash; Matur, Ramesh V; Gunneri, Subbareddy; Mogulla, Rammohan Reddy; Thammireddy, Kamal; Peta, Kalyan Kumar; Paliwal, Piyush; Mahantshetti, Niranjana S; Banala, Ramesh Kumar; Siddaiah, Prashanth
肺炎
免疫/内分泌
发表日期：2025
文献求助 收藏